IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer [Yahoo! Finance]
IDEAYA Biosciences, Inc. (IDYA)
Last ideaya biosciences, inc. earnings: 3/24 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Mon, February 10, 2025 at 12:00 PM GMT+1 3 min read In This Article IDYA SOUTH SAN FRANCISCO, Calif. Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski , Ph.D. as Chief Financial Officer. Dr. Bleharski joins IDEAYA from J.P. Morgan, where he spent nearly 17 years advising clients in the biopharma sector on capital markets transactions, corporate strategy and other investment banking services. IDEAYA anticipates that Dr. Bleharski will complete the transition into his new role by early May. (PRNewsfoto/IDEAYA Biosciences, Inc.) "We are ecstatic to welcome Josh to IDEAYA as we advance our broad potential first-in-class precision medicine oncology pipeline and build a fully integrated biotechnology company. Josh is a highly accomplished finance executive, with extensive corporate finance, strategy,
Show less
Read more
Impact Snapshot
Event Time:
IDYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDYA alerts
High impacting IDEAYA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IDYA
News
- Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial [Yahoo! Finance]Yahoo! Finance
- IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma [Yahoo! Finance]Yahoo! Finance
- IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal MelanomaPR Newswire
- IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers [Yahoo! Finance]Yahoo! Finance
- IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung CancersPR Newswire
IDYA
Earnings
- 11/4/25 - Beat
IDYA
Sec Filings
- 12/12/25 - Form 8-K
- 12/5/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- IDYA's page on the SEC website